Towa Pharmaceutical Co., Ltd.
TWAPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $441,611 | $65,149,000 | $65,857,000 | $70,333,000 |
| % Growth | -99.3% | -1.1% | -6.4% | – |
| Cost of Goods Sold | $282,541 | $41,474,000 | $41,872,000 | $44,503,000 |
| Gross Profit | $159,070 | $23,675,000 | $23,985,000 | $25,830,000 |
| % Margin | 36% | 36.3% | 36.4% | 36.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $123,667 | $18,468,000 | $18,354,000 | $18,732,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1,000 | $1,000,000 | -$1,000,000 |
| Operating Expenses | $123,667 | $18,469,000 | $19,354,000 | $17,732,000 |
| Operating Income | $35,402 | $5,206,000 | $4,631,000 | $8,098,000 |
| % Margin | 8% | 8% | 7% | 11.5% |
| Other Income/Exp. Net | $18,644 | -$1,246,000 | -$133,000 | $3,434,000 |
| Pre-Tax Income | $54,046 | $3,960,000 | $4,498,000 | $11,532,000 |
| Tax Expense | $15,507 | $1,447,000 | $136,000 | $3,463,000 |
| Net Income | $38,539 | $2,513,000 | $4,362,000 | $8,069,000 |
| % Margin | 8.7% | 3.9% | 6.6% | 11.5% |
| EPS | 0.78 | 51.05 | 88.61 | 163.92 |
| % Growth | -98.5% | -42.4% | -45.9% | – |
| EPS Diluted | 0.78 | 51.05 | 88.61 | 163.92 |
| Weighted Avg Shares Out | 49,227 | 49,227 | 49,227 | 49,227 |
| Weighted Avg Shares Out Dil | 49,227 | 49,227 | 49,227 | 49,227 |
| Supplemental Information | – | – | – | – |
| Interest Income | $615 | $0 | $0 | $0 |
| Interest Expense | $4,117 | $473,000 | $410,000 | $332,000 |
| Depreciation & Amortization | $38,241 | $5,249,000 | $5,337,000 | $5,162,000 |
| EBITDA | $96,391 | $10,456,000 | $10,968,000 | $12,260,000 |
| % Margin | 21.8% | 16% | 16.7% | 17.4% |